RxDoctor Payments Data

Dorothy Darby

Adult Health · Austin, TXNPI 1689671794

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 450 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,311in general payments, 2019–2025

Across 450 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Pfizer$1K
  • Novo Nordisk$879
  • Amgen$807
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$749
  • Johnson & Johnson$493
  • plus $4K from 30 others

What the payments were for

  • Food & beverage$9,311100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,311 in reported general payments places this provider in the 95th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab21$13,055
EntrestoSacubitril/Valsartan11$11,813
FarxigaDapagliflozin Propanediol13$3,827
Ezetimibe19$952
Metoprolol Succinate48$530
Nebivolol Hcl14$432
Atorvastatin Calcium36$424
Carvedilol41$252
ClopidogrelClopidogrel Bisulfate19$232
Rosuvastatin Calcium12$223
Potassium Chloride12$152
Losartan Potassium16$148
Spironolactone18$144
Lisinopril12$121
Amlodipine Besylate33$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,394$11,81311 claims
AstraZenecaFarxiga$394$3,82713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 adult health providers in Texas.

Other adult health in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →